Edwards Lifesciences initiated with an Outperform at Credit Suisse. Credit Suisse analyst Matt Miksic initiated Edwards Lifesciences with an Outperform rating and a price target of $188 as part of his broader research note on Medical Supplies and Devices partially titled “No Disruption, No Alpha”, calling the stock stock his top pick for exposure to Structural Heart medicine. The analyst anticipates the company to post “solid double-digit top-line growth in 2020-2022, and improving revenue mix and gross margins” with added tailwinds coming from his forecast for the addressable Transcatheter aortic valve replacement market to double in 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.